Free Trial

Telix Pharmaceuticals (TLX) Competitors

Telix Pharmaceuticals logo
$15.69 +0.21 (+1.36%)
As of 07/8/2025 04:00 PM Eastern

TLX vs. TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, VTRS, ASND, and MRNA

Should you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

Telix Pharmaceuticals vs. Its Competitors

Teva Pharmaceutical Industries (NYSE:TEVA) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Telix Pharmaceuticals has lower revenue, but higher earnings than Teva Pharmaceutical Industries.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.54B1.15-$1.64B-$1.15-14.48
Telix Pharmaceuticals$516.72M10.27$32.93MN/AN/A

Teva Pharmaceutical Industries currently has a consensus price target of $24.13, suggesting a potential upside of 44.89%. Telix Pharmaceuticals has a consensus price target of $22.33, suggesting a potential upside of 42.34%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than Telix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22
Telix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 7 mentions for Telix Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 1.08 beat Telix Pharmaceuticals' score of 0.53 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
9 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Telix Pharmaceuticals
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Telix Pharmaceuticals has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Telix Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries-7.74% 45.44% 6.95%
Telix Pharmaceuticals N/A N/A N/A

Summary

Teva Pharmaceutical Industries beats Telix Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLX vs. The Competition

MetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.24B$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E RatioN/A20.8027.0020.10
Price / Sales10.27286.27428.95120.24
Price / Cash135.6041.1936.8257.86
Price / Book14.017.487.985.56
Net Income$32.93M-$55.04M$3.16B$248.40M
7 Day Performance-4.91%2.44%2.39%4.67%
1 Month Performance-7.21%1.90%2.18%6.64%
1 Year PerformanceN/A4.35%33.82%21.31%

Telix Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLX
Telix Pharmaceuticals
N/A$15.69
+1.4%
$22.33
+42.3%
N/A$5.24B$516.72M0.00N/A
TEVA
Teva Pharmaceutical Industries
4.1934 of 5 stars
$16.76
flat
$24.13
+43.9%
+1.8%$19.22B$16.54B-14.5736,830Options Volume
INSM
Insmed
4.5528 of 5 stars
$100.64
+1.2%
$106.80
+6.1%
+37.2%$18.87B$363.71M-16.911,271Positive News
Analyst Forecast
SMMT
Summit Therapeutics
2.477 of 5 stars
$21.28
+3.3%
$35.09
+64.9%
+204.5%$15.30B$700K-62.59110
ITCI
Intra-Cellular Therapies
0.7316 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560News Coverage
GMAB
Genmab A/S
4.0028 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-16.6%$13.15B$3.12B11.742,682Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7024 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-4.7%$12.58B$3.81B22.7727,811
QGEN
Qiagen
3.8865 of 5 stars
$48.07
+0.6%
$49.40
+2.8%
+22.3%$10.62B$1.98B120.525,765
VTRS
Viatris
2.6564 of 5 stars
$8.93
-0.9%
$10.40
+16.5%
-12.7%$10.57B$14.74B-2.8232,000
ASND
Ascendis Pharma A/S
3.4843 of 5 stars
$172.60
+0.2%
$220.67
+27.8%
+23.2%$10.53B$393.54M-27.481,017
MRNA
Moderna
4.3762 of 5 stars
$27.59
+1.6%
$46.61
+68.9%
-72.1%$10.50B$3.24B-3.165,800

Related Companies and Tools


This page (NASDAQ:TLX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners